currency central- Top searches

According to data treasure statistics, excluding central enterprises and state-owned enterprises, among the above three sectors, there are 41 Shanghai local stocks with a market value exceeding 10 billion yuan.According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.After-hours big profits are related to mergers and acquisitions, restructuring, Shanghai state-owned shares have these.

Shanghai state-owned shares have these.Shanghai state-owned shares have these.According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.

As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.Among them, the market value of chip leader SMIC A shares exceeded 170 billion yuan, ranking first. According to the data, SMIC is one of the world's leading integrated circuit wafer foundry enterprises, and it is a professional wafer foundry enterprise with advanced technology, the largest scale, the most complete supporting services and transnational operation.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.